Advances and considerations in AD tau-targeted immunotherapy
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The multifactorial and complex nature of Alzheimer's disease (AD) has made it difficult to identify therapeutic targets that are causally involved in the disease process. However, accumulating evidence from experimental and clinical studies that investigate the early disease process point towards the required role of tau in AD etiology. Importantly, a large number of studies investigate and characterize the plethora of pathological forms of tau protein involved in disease onset and propagation. Immunotherapy is one of the most clinical approaches anticipated to make a difference in the field of AD therapeutics. Tau -targeted immunotherapy is the new direction after the failure of amyloid beta (Aß)-targeted immunotherapy and the growing number of studies that highlight the Aß-independent disease process. It is now well established that immunotherapy alone will most likely be insufficient as a monotherapy. Therefore, this review discusses updates on tau-targeted immunotherapy studies, AD-relevant tau species, updates on promising biomarkers and a prospect on combination therapies to surround the disease propagation in an efficient and timely manner.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194
Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Neurofilaments as biomarkers in neurological disorders
Khalil, M., Teunissen, C. E., Otto, M., Piehl, F., Sormani, M. P., Gattringer, T., Barro, C., Kappos, L., Comabella, M., Fazekas, F., et al. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0058-z · Cited by 1,988 · cited 1×
“However, the only problem with this biomarker is that it is not disease specific, rather it is neurodegeneration specific (Khalil et al., 2018).”
High performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP
Lewis, J., Dickson, D. W., Lin, W.-L., Chisholm, L., Corral, A., Jones, G., Yen, S.-H., Sahara, N., Skipper, L., Yager, D., et al. (2001) · Science · doi:10.1126/science.1058189 · Cited by 1,611 · cited 1×
“Some studies suggest that Aß malfunction lies upstream of tau malfunction and triggers tau pathology (Bloom, 2014; Hurtado et al., 2010; Lewis et al., 2001; Götz et al., 2001).”
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils
Götz, J., Chen, F., van Dorpe, J., & Nitsch, R. M. (2001) · Science · doi:10.1126/science.1062097 · Cited by 1,526 · cited 1×
“Some studies suggest that Aß malfunction lies upstream of tau malfunction and triggers tau pathology (Bloom, 2014; Hurtado et al., 2010; Lewis et al., 2001; Götz et al., 2001).”
Propagation of Tau Misfolding from the Outside to the Inside of a Cell
Frost, B., Jacks, R. L., & Diamond, M. I. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m808759200 · Cited by 1,252 · cited 2×
“Aß and tau, primarily the oligomeric species of each, have been shown to be neurotoxic both extracellularly and intracellularly (Frost et al., 2009; SebastiánSerrano et al., 2018).”
ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220 · cited 2×
“, 2018), APOE4 carriers (Safieh et al., 2019; Shi et al., 2017) , and patients with TBI history (Gerson et al.”
BackgroundMethodCSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment
Mattsson, N. (2009) · JAMA · doi:10.1001/jama.2009.1064 · Cited by 1,176
Cited by
Alzheimer’s disease: Recent treatment strategies
Vaz, M., & Silvestre, S. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173554 · Cited by 547
Biomarkers for Alzheimer’s disease—preparing for a new era of disease-modifying therapies
Zetterberg, H., & Bendlin, B. B. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0721-9 · Cited by 377
Tau-targeting therapies for Alzheimer disease: Current status and future directions
Congdon, E. E., Ji, C., Tetlow, A. M., Jiang, Y., & Sigurdsson, E. M. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00883-2 · Cited by 371
“Subsequently, numerous papers have reported effective targeting of multiple tau epitopes, including the amino terminus, the mid-domain, the microtubule-binding region, misfolded tau, p-tau202, p-tau231, p-tau396/404, p-tau409, p-tau413, p-tau422 and oligomeric tau species 57,165–172 .”
BackgroundGSK-3 and tau: a key duet in Alzheimer’s disease
Sayas, C. L., & Ávila, J. (2021) · Cells · doi:10.3390/cells10040721 · Cited by 314
“The potential therapeutic actions of these antibodies have been tested in in vivo preclinical mouse models showing to reduce tau pathology and functional deficits (reviewed in [201]).”
BackgroundSengupta, U., & Kayed, R. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102270 · Cited by 293
Self-citationImmunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Song, C., Shi, J., Zhang, P., Zhang, Y., Xu, J., Zhao, L., Zhang, R., Wang, H., & Chen, H. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00292-3 · Cited by 266
Innate Immune Cell Death in Neuroinflammation and Alzheimer’s Disease
Rajesh, Y., & Kanneganti, T.-D. (2022) · Cells · doi:10.3390/cells11121885 · Cited by 262
Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau
Mattsson‐Carlgren, N., Janelidze, S., Bateman, R. J., Smith, R., Stomrud, E., Serrano, G. E., Reiman, E. M., Palmqvist, S., Dage, J. L., Beach, T. G., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202114022 · Cited by 261
“Over the last years, there has been an increased interest in antitau treatments for AD (Bittar et al, 2020).”
BackgroundCano, A., Sánchez-López, E., Ettcheto, M., López-Machado, A., Espina, M., Souto, E. B., Galindo, R., Camins, A., García, M. L., & Turowski, P. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0443 · Cited by 144
Pharmacotherapy Evolution in Alzheimer’s Disease: Current Framework and Relevant Directions
Miculas, D. C., Negru, P. A., Bungau, S. G., Behl, T., Hassan, S. S. U., & Tit, D. M. (2022) · Cells · doi:10.3390/cells12010131 · Cited by 96
“Therefore, utilizing drugs that simultaneously target both of these proteins may be more beneficial than a single therapy that only targets one [89,90].”
BackgroundTau immunotherapies: Lessons learned, current status and future considerations
Sandusky-Beltran, L. A., & Sigurdsson, E. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108104 · Cited by 90
Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61
Tau; One Protein, So Many Diseases
Tabeshmehr, P., & Eftekharpour, E. (2023) · Biology · doi:10.3390/biology12020244 · Cited by 33
Arfaei, R., Mikaeili, N., Daj, F., Boroumand, A., Kheyri, A., Yaraghi, P., Shirzad, Z., Keshavarz, M., Hassanshahi, G., Jafarzadeh, A., et al. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112328 · Cited by 27
Current peptide vaccine and immunotherapy approaches against Alzheimer’s disease
Parrocha, C. M. T., & Nowick, J. S. (2023) · Peptide Science · doi:10.1002/pep2.24289 · Cited by 24
Bittar, A., Al-Lahham, R., Bhatt, N., Moore, K., Montalbano, M., Jerez, C., Fung, L., McAllen, S., Ellsworth, A., & Kayed, R. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220518 · Cited by 18
“Reduction of tau oligomers coincides with a reduction of disease-related pathology and a significant improvement in the memory and cognitive functions in different animal models [7, 14–20].”
InfluentialSelf-citation
Metadata
- Authors
- Bittar, A., Bhatt, N., & Kayed, R.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2020-02
- Volume
- 134
- Pages
- 104707
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2995934239
- Cited by
- 104
- References
- 66
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.